Search

Author/Creator Brander, Danielle M

1. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Issue 8 (August 2019)

Authors:
Davids, Matthew S; Brander, Danielle M; Kim, Haesook T; Tyekucheva, Svitlana; Bsat, Jad; Savell, Alexandra; Hellman, Jeffrey M; Bazemore, Josie; Francoeur, Karen; Alencar, Alvaro; Shune, Leyla; Omaira, Mohammad; Jacobson, Caron A; Armand, Philippe; Ng, Samuel; Crombie, Jennifer; LaCasce, Ann S; A...
Journal:
Lancet
Issue:
Volume 6:Issue 8(2019)
Page Start:
e419
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Issue 9 (September 2016)

Authors:
Strati, Paolo; Lanasa, Mark; Call, Timothy G; Leis, Jose F; Brander, Danielle M; LaPlant, Betsy R; Pettinger, Adam M; Ding, Wei; Parikh, Sameer A; Hanson, Curtis A; Chanan-Khan, Asher A; Bowen, Deborah A; Conte, Michael; Kay, Neil E; Shanafelt, Tait D
Journal:
Lancet
Issue:
Volume 3:Issue 9(2016)
Page Start:
e407
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Issue 4 (April 2021)

Authors:
Sharman, Jeff P; Brander, Danielle M; Mato, Anthony R; Ghosh, Nilanjan; Schuster, Stephen J; Kambhampati, Suman; Burke, John M; Lansigan, Frederick; Schreeder, Marshall T; Lunin, Scott D; Zweibach, Alexander; Shtivelband, Mikhail; Travis, Patrick M; Chandler, Jason C; Kolibaba, Kathryn S; Sportel...
Journal:
Lancet
Issue:
Volume 8:Issue 4(2021)
Page Start:
e254
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Issue 4 (April 2018)

Authors:
Burris, Howard A; Flinn, Ian W; Patel, Manish R; Fenske, Timothy S; Deng, Changchun; Brander, Danielle M; Gutierrez, Martin; Essell, James H; Kuhn, John G; Miskin, Hari P; Sportelli, Peter; Weiss, Michael S; Vakkalanka, Swaroop; Savona, Michael R; O'Connor, Owen A
Journal:
Lancet oncology
Issue:
Volume 19:Issue 4(2018)
Page Start:
486
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Issue 2 (February 2017)

Authors:
Seymour, John F; Ma, Shuo; Brander, Danielle M; Choi, Michael Y; Barrientos, Jacqueline; Davids, Matthew S; Anderson, Mary Ann; Beaven, Anne W; Rosen, Steven T; Tam, Constantine S; Prine, Betty; Agarwal, Suresh K; Munasinghe, Wijith; Zhu, Ming; Lash, L Leanne; Desai, Monali; Cerri, Elisa; Verdugo...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 2(2017:Feb.)
Page Start:
230
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Issue 8 (August 2022)

Authors:
Tam, Constantine S; Brown, Jennifer R; Kahl, Brad S; Ghia, Paolo; Giannopoulos, Krzysztof; Jurczak, Wojciech; Šimkovič, Martin; Shadman, Mazyar; Österborg, Anders; Laurenti, Luca; Walker, Patricia; Opat, Stephen; Chan, Henry; Ciepluch, Hanna; Greil, Richard; Tani, Monica; Trněný, Marek; Brander, ...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 8(2022)
Page Start:
1031
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗